title: The safety of incretin based drug treatments for type 2 diabetes.
authors.affiliation: Division of General Internal Medicine, Department of Medicine, The MetroHealth System/Case Western Reserve University, Cleveland, OH, USA Department of Epidemiology and Biostatistics, Case Western Reserve University sdb73@case.edu.
authors.forename: Shari D
authors.initials: SD
authors.lastname: Bolen
authors.affiliation: Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA.
authors.forename: Nisa M
authors.initials: NM
authors.lastname: Maruthur
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D054795:Incretins / Q000009:adverse effects*; D008297:Male; D010190:Pancreatic Neoplasms / Q000139:chemically induced*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins